European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Sahra, Camarero, Jorge, van Hennik, Paula, Bolstad, Bjorg, Sommerfelt Grønvold, Maja, Syvertsen, Christian, Oddvar Strøm, Bjorn, Ökvist, Mats, Josephson, Filip, Keller-Stanislawski, Brigitte, Zafiropoulos, Nikolaos, Pean, Elias, Bergh, Jonas, da Rocha Dias, Silvy, Pignatti, Franscesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668381/
https://www.ncbi.nlm.nih.gov/pubmed/33188050
http://dx.doi.org/10.1136/esmoopen-2020-000798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668381/
https://www.ncbi.nlm.nih.gov/pubmed/33188050
http://dx.doi.org/10.1136/esmoopen-2020-000798

Ejemplares similares